Tieton Capital Management LLC purchased a new stake in shares of Chromadex Corp (OTCMKTS:CDXC) during the first quarter, Holdings Channel reports. The institutional investor purchased 688,735 shares of the company’s stock, valued at approximately $1,853,000. Chromadex Corp makes up approximately 1.6% of Tieton Capital Management LLC’s investment portfolio, making the stock its 26th largest position.
Chromadex Corp (OTCMKTS:CDXC) traded up 3.56% during midday trading on Friday, reaching $3.20. The company had a trading volume of 208,159 shares. The stock’s 50 day moving average price is $2.89 and its 200-day moving average price is $2.79. Chromadex Corp has a one year low of $2.25 and a one year high of $5.95. The firm’s market capitalization is $127.33 million.
Chromadex Corp (OTCMKTS:CDXC) last announced its quarterly earnings results on Thursday, March 16th. The company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by $0.05. The company had revenue of $5.64 million for the quarter, compared to analyst estimates of $5.60 million. On average, equities research analysts anticipate that Chromadex Corp will post $0.16 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Mideast Time and is owned by of Mideast Time. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.mideasttime.com/688735-shares-in-chromadex-corp-cdxc-acquired-by-tieton-capital-management-llc/1708904.html.
CDXC has been the topic of a number of recent research reports. Zacks Investment Research raised Chromadex Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, March 14th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Chromadex Corp in a research report on Thursday, February 16th.
About Chromadex Corp
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chromadex Corp (OTCMKTS:CDXC).
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.